Altered prostaglandin E1 dosage during extracorporeal membrane oxygenation in a newborn with ductal-dependent congenital heart disease

We describe a neonate with ductal-dependent congenital heart disease on extracorporeal membrane oxygenation (ECMO) for persistent pulmonary hypertension, who required markedly high doses of prostaglandin E1 (PGE1) to maintain patency of the ductus arteriosus: The effects of ECMO on the pharmacokinet...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric cardiology 2006-06, Vol.27 (3), p.360-363
Hauptverfasser:	Stone, D M, Frattarelli, D A C, Karthikeyan, S, Johnson, Y R, Chintala, K
Format:	Artikel
Sprache:	eng
Schlagworte:	Alprostadil - administration & dosage Alprostadil - metabolism Ductus Arteriosus, Patent - diagnostic imaging Extracorporeal Membrane Oxygenation Female Heart Defects, Congenital - diagnostic imaging Heart Defects, Congenital - therapy Humans Hypertension, Pulmonary - congenital Hypertension, Pulmonary - therapy Infant, Newborn Meconium Aspiration Syndrome - therapy Pulmonary Valve Stenosis - therapy Ultrasonography Vasodilator Agents - administration & dosage Vasodilator Agents - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We describe a neonate with ductal-dependent congenital heart disease on extracorporeal membrane oxygenation (ECMO) for persistent pulmonary hypertension, who required markedly high doses of prostaglandin E1 (PGE1) to maintain patency of the ductus arteriosus: The effects of ECMO on the pharmacokinetics of PGE1 are discussed.
ISSN:	0172-0643 1432-1971
DOI:	10.1007/s00246-005-1189-8